目的 观察盐酸法舒地尔联合奥扎格雷钠对短暂性脑缺血发作的临床疗效和安全性.方法 将60例短暂性脑缺血发作患者随机均分为两组,治疗组用盐酸法舒地尔30 mg静脉滴注,12h滴完,奥扎格雷钠80 mg静脉滴注,12h滴完,均连用14 d;对照组单用奥扎格雷钠80mg静脉滴注,12h滴完,连用14d.观察两组临床疗效和不良反应,检测血常规、尿常规、肝功能、肾功能以及凝血指标.结果 两组基本痊愈率比较差异有统计学意义(P0.05);治疗组短暂性脑缺血发作停止时间早于对照组.两组均无明显不良反应,血常规、尿常规、肝功能、肾功能以及凝血指标无明显改变.结论 盐酸法舒地尔联合奥扎格雷钠治疗短暂性脑缺血发作不但能够提高疗效,而且安全,可以考虑将其试用于短暂性脑缺血发作的治疗.%Objective To investigate the clinical efficacy and safety of fasudil hydrochloride combined with sodium ozagrel in treatment of transient ischemic attack(TIA). Methods Sixty patients with TIA were enrolled in the study and divided into the treatment group and the control group randomly and evenly. The treatment group was treated with fasudil hydrochloride 30 mg by intravenous drip and the control group with intravenous sodium ozagrel 80 mg alone for 14 d. The clinical efficacies and adverse reactions were observed. The blood routine,urine routine, liver and renal functions and the indexes of blood clotting were detected. Results The basic recovery rate of the treatment group was significantly higher than that of the control group( P ＜ 0. 05), but the total excellent effective rate had no significant difference between the two groups( P ＞ 0. 05). The time of stopping attack in the treatment group was shorter than that of the control group. No obvious adverse reactions occurred in the two groups. The blood routine, urine routine, liver and renal functions and coagulation indexes all had no significant changes. Conclusion It is possible to treat TIA with fasudil hydrochloride combined with sodium ozagrel, which not only improves the efficacy but also has safety.
展开▼
